Why U.S. Drug Prices Subsidize the World - Ending America’s Role as Pharma Piggy Bank

The prices of on-patent drugs in the United States are many multiples of the prices of exactly identical drugs from the very same manufacturing plants sold elsewhere in the world.  To some extent, this reflects price controls imposed on the pharmaceutical industry by foreign countries, but there is more going on here.

Charles Rotter discusses how foreign countries free ride on American pharmaceutical research, driving up American consumers' costs while reducing their residents' costs:

https://x.com/crotter8/status/1911982801584275679

America’s Hidden Pharmaceutical Foreign Aid: Why U.S. Drug Prices Subsidize the World
American patients often pay far more for prescription drugs than their peers abroad – so much more, in fact, that U.S. consumers are effectively subsidizing cheaper medicines for Canada, Europe, and other countries. This pricing structure acts as a hidden form of foreign aid, one not approved by Congress but extracted through sky-high domestic drug prices. On average, Americans pay 2 to 3 times what patients in other developed nations pay for the same medications​.

Drug companies often justify U.S. price premiums by pointing to research and development costs and the need to fund innovation. Indeed, America’s outsize spending has helped it become a world leader in new drug development, accounting for a disproportionate share of global pharmaceutical sales.​

But this system also means Americans shoulder an unfair share of the cost burden. Policies in other countries force drugs to be sold below what a free market might dictate, and drugmakers make up the difference by charging Americans more​.
It is “well-known that Americans unfairly subsidize biopharmaceutical innovation for the world,” as one policy analysis noted, with the U.S. paying significantly more for the same medications than nations with government price controls​.

​A 2015 Reuters analysis found U.S. prices for the 20 top-selling drugs were triple those in Britain, making America “by far the most profitable market” for pharmaceutical companies and “leading to complaints that Americans are effectively subsidizing health systems elsewhere.”​

In other words, U.S. drug pricing has become a de facto global subsidy, with American wallets funding discounts abroad.

Price Disparities: Americans Pay More so Others Can Pay Less

Pharmaceutical manufacturers prioritize high prices in the U.S. while accepting steep discounts in secondary markets like Canada and Europe. Other governments leverage bulk purchasing and price controls to negotiate dramatically lower rates than what Americans are charged. For example, Canada directly regulates drug prices​ and most European countries have government-run health systems that bargain hard with drugmakers. Because the U.S. largely leaves pricing to the market, companies can charge whatever the traffic will bear – and they do. The result is a staggering price gap: U.S. prescription drug prices average about 2.78 times higher than those in 33 other nations (and over 4 times higher for brand-name drugs)​.

Over the past 15 years, foreign “free-riding” has only increased – prices for many top drugs in Europe fell from about 51% of U.S. prices to just 32% by 2017, leaving Americans to pay a greater share of R&D costs​

In essence, other countries’ healthcare systems stay sustainable and affordable because American patients bankroll the difference​
This implicit cross-subsidy may benefit patients in London or Toronto, but it leaves patients in Los Angeles and Tampa with unreasonably high bills.

The Battle Over Reimportation: Stopping the “Subsidy” at the Border

Faced with stark price differences, many Americans have logically asked: why not just buy cheaper drugs from abroad? This idea of reimportation – bringing back U.S.-made drugs sold at lower prices overseas – has strong public appeal and bipartisan support​. More than 2 million Americans (about 1.5% of adults) already purchase prescription medications from outside the U.S. to save money, despite legal hurdles​. Bus trips to Canadian pharmacies and online international orders have become a lifeline for patients struggling with costs. In response, policymakers have pushed to formally allow importation of lower-priced drugs, especially from Canada, to give consumers relief.

However, the fight over reimportation has been fierce, with heavy pushback from drug manufacturers and regulators at every turn. For two decades, federal law has technically allowed importation if the Health and Human Services (HHS) secretary certifies it is safe and will save money, but no administration would give that sign-off – effectively blocking import programs​. Pharmaceutical companies vehemently oppose bulk importation, fearing it would undercut their U.S. profits. The industry lobby argues that allowing Americans to buy at Canada’s prices would “circumvent controls that keep drugs safe” and undermine the secure U.S. supply chain​. Critics note this safety concern is often a smokescreen for protecting profits. In reality, many drugs sold in Canada are made in the same FDA-inspected facilities as U.S. versions. The real threat for Big Pharma is losing the ability to price-gouge Americans.

Even when the previous Trump administration finally authorized a pathway for state-level importation in 2020 – with HHS Secretary Alex Azar certifying it posed “no risk” to public safety and would significantly cut costs​– practical roadblocks remain. The FDA approved Florida’s importation plan in January 2024, theoretically clearing the way for that state to bring in medications from Canada​. Yet drugs have still not begun flowing. Canada has erected export restrictions to protect its own supply, barring sales abroad that could cause shortages​​. And pharmaceutical companies refuse to play ball, indicating they won’t send extra inventory to Canada beyond what its population needs​. “The likelihood of this actually materializing is negligible,” one expert noted, since drugmakers “are not going to oversupply the Canadian market.”​

Unsurprisingly, the industry also took the fight to court – the major drug lobby (PhRMA) sued the federal government in 2020 to block the importation program, seeking to kill it before it starts​. All this resistance has stalled efforts to end what is, in effect, an arbitrage opportunity born of international price discrimination. For now, American patients remain largely locked into the highest prices and unable to easily reap the benefits of the “discount” markets their dollars help support.

“America First” – Except on Drug Prices?

This status quo stands in glaring contrast to the “America First” ethos that has gained prominence under the current Trump administration. A core tenet of America First is that the U.S. should stop letting other nations take advantage of American generosity or wealth. The Trump White House has moved aggressively to eliminate policies that it saw as exploiting the U.S. – cutting or freezing foreign aid, pulling out of international agreements, and demanding allies shoulder more costs. In the early days of this agenda, the administration imposed a 90-day freeze on most foreign aid spending and withdrew the United States from the World Health Organization (WHO) and the Paris Climate Accord, moves meant to signal that American interests come first​. President Trump ordered a sweeping review of U.S. foreign assistance to ensure taxpayer funds weren’t being “blindly” doled out with no benefit to Americans​. The message was clear: no more free rides on America’s dime.

Yet when it comes to prescription drugs, Americans still continue to bankroll a big portion of the world’s healthcare with little in return. The hidden foreign aid flowing via Pharma pricing would seem to violate the very spirit of “America First.” Why should a senior in the U.S. pay dramatically more for the same pill than a senior in France, effectively subsidizing France’s national health system? In a truly America-first approach, U.S. consumers would not be the ones propping up foreign drug price controls. Notably, even the Trump administration acknowledged this imbalance and took aim at it. In late 2020, President Trump announced a “Most Favored Nation” policy – encapsulated in an executive order bluntly titled “Lowering Drug Prices by Putting America First”​. The order sought to ensure that Medicare would pay no more for medicines than the lowest price that drugmakers charge in other developed countries​. The logic was straight from Trump’s playbook: if Germany or Canada negotiates a rock-bottom price, then American programs should get that same deal, rather than paying a premium that effectively subsidizes the discount. (Pharmaceutical companies, unsurprisingly, howled in protest and the rule was tangled up in litigation and eventually revoked before it could take effect.)

The broader point stands: leaders from both parties now recognize that American patients have been footing the bill for the rest of the world. Trump-era officials decried the “foreign free-riding” on U.S. drug innovation​, while Democrats in Congress have likewise slammed the price gap as unfair to Americans. Ending this implicit subsidy should be a national priority consistent with putting U.S. consumers first.

Time for a New Policy: Ending America’s Role as Pharma Piggy Bank

It’s untenable for Americans to continue shouldering the world’s drug costs. A new policy framework is needed – one that levels the playing field and stops forcing U.S. consumers to pay marked-up prices while others enjoy bargains. In practical terms, this means pursuing legislative and regulatory solutions to close the price disparity:

International Reference Pricing: One approach is to peg U.S. drug prices to those in other wealthy countries. For instance, the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) – passed by the House in 2019 – would have empowered Medicare to negotiate prices with drug companies, with a ceiling tied to an average of prices in countries like Canada, the UK, France, and others​. Under that bill, a drug’s U.S. price could be no higher than 120% of the average price across six high-income nations (and no lower than the cheapest)​. Even the scaled-back measures in the recent Inflation Reduction Act will finally allow Medicare to start negotiating a handful of drug prices in 2026​. Going forward, international price indexing could be expanded so that Americans never pay more than, say, the OECD average for a given medication. Tying U.S. prices to global benchmarks would force drugmakers to spread R&D costs more evenly, rather than loading the lion’s share onto America​.

International Reference Pricing: One approach is to peg U.S. drug prices to those in other wealthy countries. For instance, the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) – passed by the House in 2019 – would have empowered Medicare to negotiate prices with drug companies, with a ceiling tied to an average of prices in countries like Canada, the UK, France, and others. Under that bill, a drug’s U.S. price could be no higher than 120% of the average price across six high-income nations (and no lower than the cheapest). Even the scaled-back measures in the recent Inflation Reduction Act will finally allow Medicare to start negotiating a handful of drug prices in 2026. Going forward, international price indexing could be expanded so that Americans never pay more than, say, the OECD average for a given medication. Tying U.S. prices to global benchmarks would force drugmakers to spread R&D costs more evenly, rather than loading the lion’s share onto America.

Allow Safe Reimportation: Breaking the ban on importing lower-cost drugs could instantly arbitrage away extreme price differences. With proper safeguards – verified suppliers, FDA monitoring, anti-counterfeit measures – Americans should be allowed to buy medicines from trusted countries like Canada and the EU. Legislation or waivers could sanction licensed pharmacies or wholesalers to import FDA-approved drugs that are made by the same manufacturers but sold for less abroad. This would effectively create competition for U.S. prices and pressure companies to cut domestic prices or lose sales to imports. Recent moves by states (like Florida’s importation program) and the federal government to enable pilot importation are steps in this direction, but they need to be implemented in earnest, not stalled by bureaucratic hurdles or lawsuits. If the pharmaceutical industry truly fears unsafe or diverted drugs, it can solve that by offering Americans the same fair prices it offers Canadians.

Transparency and Fairness Measures: At the very least, drug companies should have to disclose international pricing and justify why U.S. prices are higher. Greater transparency would illuminate the extent of the disparities and potentially shame companies into moderating their U.S. markups. Congress could require reporting of list prices and net prices by country, as well as R&D cost recoupment data, to inform more equitable pricing policies. Another idea is imposing penalties or tax consequences on excessive price discrimination – for example, if a company charges American consumers more than, say, twice the price it charges in other G7 nations, it could face an excise tax or lose certain U.S. patent perks. Such measures would incentivize narrowing the gap. Additionally, the U.S. Trade Representative could be enlisted to negotiate with trading partners so they raise their price floors (paying closer to true market value) while the U.S. lowers its price ceilings, meeting somewhere in the middle. The end goal is a fair cost-sharing arrangement instead of the current lop-sided model.

Critics of these reforms often warn that lower U.S. prices might reduce drug innovation, since pharma companies claim they rely on American profits to fund research. While innovation is critical, the answer cannot be to indefinitely gouge Americans and call it “R&D funding.” The industry’s threats to curtail research should be taken with a grain of salt – after all, the U.S. market would still be enormously lucrative, just not unconstrained in its pricing. Moreover, other wealthy nations can and should contribute more to the innovation kitty by paying their fair share for new breakthrough drugs, rather than riding free on America’s willingness to pay any price. It’s neither sustainable nor ethical to maintain a system where a cancer patient in Texas pays double or triple what a patient in Toronto does for the same therapy, simply because of where they live.

Americans have long been told that we enjoy the “newest” and “best” pharmaceuticals​thanks to our system. But that rings hollow when millions of Americans skip doses or go into debt because of drug costs, even as foreign patients get affordable access to those same meds. Eighty percent of Americans believe drug prices are unreasonable​, and for good reason. The hidden foreign aid flowing out of American medicine cabinets and checkbooks is neither visible nor voluntary, but it is painfully felt. It’s time to put America first in pharmaceutical policy by ending the global free ride on U.S. consumers. By enacting common-sense measures – from international price indexing to safe importation – we can prevent Americans from shouldering the cost burden for the rest of the world’s drugs and ensure that our own patients come first for a change.

Sources:

Rich & Marar, Reason – “How America subsidizes medicine across the world,” Sept. 5, 2024​
Hirschler, Reuters – “Transatlantic divide: how U.S. pays three times more for drugs,” Oct. 12, 2015​.
Mulcahy et al., RAND Corporation – U.S. vs. international drug price study (2024)​.
Kaiser Health News/WUSF News – “Florida isn’t alone in challenging Biden over allowing Canada drug imports,” Dec. 14, 2022​​.
Ollstein, Politico – “The FDA just cleared the way for drug importation. What now?” Jan. 5, 2024​.
Pease, University of Florida News – “2 million Americans buy prescription drugs outside the country,” June 29, 2020​.
Singer, Project Syndicate – “America First” in Action,” Feb. 6, 2025​.
Mason & Wroughton, Reuters – Trump foreign aid review, March 5, 2025​.
Sidley Austin LLP – Summary of Trump’s “Lowering Drug Prices by Putting America First” executive order (Sept. 13, 2020)​​.
America First Policy Institute – “Lower Prescription Drug Prices” (2022)​​.
Commonwealth Fund – Explainer on H.R.3 Lower Drug Costs Now Act (Apr. 9, 2020)​.
KFF Issue Brief – “FAQs on Prescription Drug Importation” (Feb. 2023)​​.